Danaher Exceeds Q1 Adjusted EPS Estimates, Revenue Also Tops Forecasts
DHR is trading near its 52-week low of $180.03 (10% above the low).
Summary
Danaher reported strong first-quarter results, with adjusted EPS of $2.06 significantly surpassing the IBES estimate of $1.94. Revenue also slightly exceeded expectations, coming in at $6.0 billion against an estimate of $5.997 billion. The company's full-year adjusted EPS outlook of $8.35-$8.55 is largely in line with the consensus estimate of $8.40. This positive earnings beat, particularly on the bottom line, indicates solid operational performance and is likely to be viewed favorably by the market. This news follows the company's recent establishment of a new $5.0 billion revolving credit facility, a separate financing event. Traders will be watching for further details on segment performance and any potential revisions to the full-year guidance.
At the time of this announcement, DHR was trading at $198.93 on NYSE in the Life Sciences sector, with a market capitalization of approximately $138.4B. The 52-week trading range was $180.03 to $242.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.